The inclusion of gaming disorder (GD) as an official diagnosis in the ICD-11 was a significant milestone for the field. However, the optimal measurement approaches for GD are currently unclear. This comprehensive systematic review aimed to identify and evaluate all available English-language GD tools and their corresponding evidence. A search of PsychINFO, PsychArticles, ScienceDirect, Scopus, Web of Science, and Google Scholar identified 32 tools employed in 320 studies (N=462,249 J o u r n a l P r e -p r o o f Journal Pre-proof participants). The evaluation framework examined tools in relation to: (1) conceptual and practical considerations; (2) alignment with DSM-5 and ICD-11 criteria; (3) type and quantity of studies and samples; and (4) psychometric properties. The evaluation showed that GD instrumentation has proliferated, with 2.5 tools, on average, published annually since 2013. Coverage of DSM-5 and ICD-11 criteria was inconsistent, especially for the criterion of continued use despite harm. Tools converge on the importance of screening for impaired control over gaming and functional impairment. Overall, no single tool was found to be clearly superior, but the AICA-Sgaming, GAS-7, IGDT-10, IGDS9-SF, and Lemmens IGD-9 scales had greater evidential support for their psychometric properties. The GD field would benefit from a standard international tool to identify gaming-related harms across the spectrum of maladaptive gaming behaviors.
The present review aimed primarily to evaluate all available GD and related instruments and their associated empirical evidence base. Although numerous tools refer to IGD in their name and/or source publication, which is the construct used in the DSM-5, this review uses the abbreviation GD to encompass both the DSM-5 and ICD-11 classifications, including when referring to all tools and constituent items. A secondary aim of this review was to provide insights into the nature and quality of the overall evidence base on GD. This evaluation was guided by a similar previous major review conducted by King et al. (2013) prior to the inclusion of IGD as a condition for further study in the DSM-5. It was reasoned that the 2013 review should be updated given that new data may often inform a new consensus on a topic, particularly in a rapidly changing field. The Cochrane Collaboration, for example, recommends that systematic reviews are updated every two years (Moher et al., 2008) .
The 2013 systematic review was informed by standards in psychological assessment (Cicchetti, 1994; Groth-Marnat, 2009 ), which were incorporated into the new framework for the present review. The 2013 review highlighted some of the conceptual inconsistencies across GD tools, as well as gaps in empirical evidence underlying available measures' psychometric properties. In addition to describing the conceptual and practical considerations of all GD tools, the present review sought to address basic questions of: (1) whether current tools were consistent with the DSM-5 and ICD-11 criteria;
(2) which tools were being used in which specific research areas (i.e., epidemiological, neurobiological, interventions) ; and, (3) which tools had received relatively greater evidential support for their psychometric properties.
Methods

Identification and selection of tools
This review aimed to identify and examine all available instruments for screening or assessing problematic gaming and/or GD. Tools were selected for inclusion if they met the following criteria:
(1) peer-reviewed and published in English language; (2) accessibility of all test items and response categories (e.g., list in appendix section, or analysis of test items, e.g., factor analysis); (3) primarily designed to measure problematic gaming or gaming disorder, and not internet addiction or other condition (NB: an exception was made for widely used internet addiction tests that refer specifically to gaming activities, e.g., the Young Internet Addiction Test [YIAT; Young, 1998 ] and Compulsive Internet Use Scale [CIUS; Meerkerk, Van Den Eijnden, Vermulst, & Garretsen, 2009) , and for the Screener for Substance and Behavioural Addictions [SSBA; Schluter, Hodgins, Wolfe, & Wild, 2018] as a behavioral addiction tool); (4) the test was self-report (i.e., not completed by an external rater, e.g., parent); and, (5) the test was original and not a composite of two or more existing measures and/or adapted DSM or other diagnostic criteria (e.g., alcohol-use disorder criteria adapted to gaming). A database search was conducted on 4 April 2019 by the first author (DLK). The Google Scholar and academic databases, including PsychINFO, PsychArticles, PubMed, ScienceDirect, Scopus, and Web of Science, were searched using the following keywords and protocol: ((measure or tool or test or validation or psychometric or screening or diagnostic or item or instrument) AND gaming). Figure 1 presents a PRISMA summary of the database search that yielded a total of 5,828 results (including duplicate results). The titles and abstracts of all results generated by each database were screened for relevance using the above inclusion criteria, which led to the identification of 32 tools, including tests with multiple item formats (see Table 1 for the complete list).
Identification of empirical literature underlying tools
The second phase of the search protocol involved identifying all empirical studies that have employed at least one of the identified 32 tools. This search protocol involved a procedural examination of the Google Scholar citation records for all identified tools (as of April 2019). Google Scholar was used because it is rapidly updated to include new results across multiple academic databases. Table 3 provides a summary of the citation records for each tool; citation counts were highly variable and ranged between no citations and 5,413 citations. The total citation count for all tools combined was 12,996 (NB: papers citing a paper that presented multiple versions of a tool were counted only once). These records were examined to identify empirical studies published in English. There were no restrictions on inclusion of studies based on study type (e.g., intervention, epidemiological, neurobiological), publication date, or any potential methodological shortcomings. However, articles that were not peer-reviewed (e.g., dissertation material, conference proceedings) were excluded. Supplementary material 1 presents a numbered list of 328 references, with each number corresponding to the evidence cited in superscript format in Tables 5 and 6.
Tools evaluation framework
This review aimed to provide a comprehensive descriptive summary and critical evaluation of the conceptual and psychometric properties, and practical considerations, of all 32 identified tools. This evaluation was conducted in stages under the guidance and collaboration of members of the research team, which was composed of 14 experts (i.e., psychiatrists, research professors, psychometrician, clinical psychologists) in the field of GD and behavioral addictions. This review was informed by the structure and protocols of the previous systematic review of GD tools conducted by King et al. (2013) . The 2013 review was based on 18 tools (N=63 studies) published up to 2012, and therefore preceded the DSM-5 and ICD-11 recognition of GD (NB: the DSM-5 has only recognized IGD as a provisional disorder, or condition in need of further study). The present review sought to address the question of whether available tools were consistent with, and capable of, assessing IGD/GD as described in the DSM-5 and ICD-11 classifications. The 2013 framework was guided by JARS reporting standards (APA Publications and Communications Board Working Group, 2008) , as well as Cicchetti's (1994) and Groth-Marnat's (2009) criteria and guidelines for evaluating psychological tests.
The present review aimed to incorporate the 2013 review's framework components, as well as extend the previous review by including more advanced psychometric information. All tools and studies evaluated in this review (i.e., the master spreadsheets underlying all analyses in this review, which were created by DLK) were checked by at least 3 members of the research team (i.e., JB, NC, and PHD). Any discrepancies or errors in ratings or data entry were resolved by consultation among authors. At every stage of the review process, all members of the research team were provided with relevant updates and documentation outlining the procedures and results. All members were invited to contribute any feedback or other observations on this material. All feedback and suggestions were responded to as team messages for transparency. As explained in Section 2.3.4, there was a roundtable discussion attended in person by 14 team members at the 6 th International Conference on Behavioral Addictions in Yokohama, Japan, which enabled discussion of the review's content (distributed electronically before the meeting) and reach consensus decisions on how to present this information in tabular format for a final report.
Review framework I: Overview
First, all 32 tools were summarized according to the following basic characteristics: (1) tool abbreviation (i.e., tool acronym or short-hand name; some tools were disambiguated by using new terms, e.g., 'Petry IGD' and 'Lemmens IGD' to minimise potential confusion with other scales with IGD as their namesake); (2) author and date (derived from original publication source); (3) tool components (i.e., constructs reportedly measured by the tool); (4) number of items (i.e., all tool items, including those which may not be included in scoring considerations (e.g., the AICA-Sgaming and C-VAT2.0 include additional items for clinical judgement but are not scored); (5) response format (i.e., response options for tool items, e.g., yes/no); (6) cut-off score (i.e., cut-off for 'problematic' or 'addicted' status on the test, based on original source reference, if reported); (7) age (i.e., participant with the lowest age who completed the tool in the original study); (8) country of origin (i.e., country of research team's institution, with priority given to first author); and, (9) language versions (i.e., known language versions of the tool, based on the published evidence base only).
Review framework II: DSM/ICD coverage
The second step involved evaluation of each tool's coverage of the DSM-5 and ICD-11 criteria for IGD/GD. Variation in coverage of criteria or guidelines is important because it may, for example, affect prevalence rates in epidemiological studies or affect diagnostic specificity in clinical practice. At the same time, it is acknowledged that total coverage of DSM/ICD criteria is not essential for the purpose of screening, where having fewer items is considered more feasible for the purpose of obtaining insights into, or estimates of, potential harms. Each test's description of its components (i.e., symptoms) were compared to each of the criteria in their respective DSM-5 and ICD-11 categories. The DSM-5 criteria included 9 symptoms (see American Psychiatric Association, 2013); the ICD-11 guidelines included 3 criteria (i.e., 1: impaired control, 2: increasing priority given to gaming; 3: continuation of gaming despite harm; see WHO, 2019) and then functional impairment which was delineated into 5 main areas (i.e., personal [psychological/physical well-being], social, education, work, and financial). The Table 2 legend provides further information on each type of impairment. The rationale for delineating impairment types was to identify tools that may provide contextually useful information on gaming-related consequences, such as greater applicability to certain investigations (e.g., studies of social correlates of gaming) or special populations (e.g., school-related consequences of excessive gaming).
Review framework III: Quantifying the evidence base
The third step of the evaluation involved a detailed summary of the empirical evidence base for all 32 tools. The evidence was summarized according to: (1) Google Scholar citation count (i.e., all citations, irrespective of publication type); (2) Number of empirical studies (i.e., studies that employed the tool, excluding any non-quantitative studies); (3) Validation studies (i.e., studies that involved tool validation based on nationally representative or clinical samples, delineating studies according to those conducted by: (i) the tool's original author, and (ii) independent research teams); (4) Intervention studies (i.e., studies involving any type of intervention, e.g., psychotherapy, prevention); (5) Clinical sample (i.e., participants with diagnosed GD or probable GD using a structured clinical interview by a psychiatrist, clinical psychologist, or qualified registrar; participants seeking treatment for GD; and both aforementioned scenarios); (6) Longitudinal studies (i.e., studies with repeated observations of the same sample, with no restriction on intervals between observations); (7) Prevalence studies (i.e., studies yielding a GD prevalence rate based on a nationally representative sample or subsample [e.g., adolescents] of the population), and; (8) Neurobiological studies (i.e., studies that employ imaging technologies, such as functional magnetic resonance imaging (fMRI), and/or neurocognitive measures. In addition, a descriptive summary of the samples' size and age composition, and recruitment approaches, associated with each tool was generated. The review framework delineated: (1) Total N (i.e., the total number of participants who have been administered the tool across all studies); (2) Participant age (i.e., adolescent [<18 years] vs. adult age); and (3) recruitment strategy (i.e., convenience vs non-convenience sampling). This information was then used to calculate the relative proportion of age groups and convenience sampling for each tool.
Review framework IV: Psychometric properties of tools
The fourth step of the review summarized the research evidence on each test's psychometric properties. The broad aim was to determine the nature, quantity, and overall consistency of research support for each tool's validity and reliability. Applying the framework published by King et al. (2013) , and extending this framework to consider new areas of test refinement and clinical utility, this undertaking considered the following areas for evaluation: (1) Dimensionality (i.e., type of statistical analysis, e.g., exploratory factor analysis; results, e.g., 1-factor solution); (2) Reliability (i.e., internal consistency, test-retest coefficients); (3) Refinement (i.e., results of Rasch analysis, item response theory [IRT], measurement invariance); (4) Validity (i.e., convergent, criterion); (5) Relationship to impairment (i.e., association with recognized measure of functional impairment); and, (6) Clinical use (i.e., known utility within a clinical interview; use as an outcome measure for a structured intervention).
Information on each of the above psychometric areas was extracted by systematic review of each of the 328 articles for compilation into Excel spreadsheets. This process was assisted by the advanced search function in Acrobat Reader DC to identify relevant keywords. For example, the keyword 'factor' was used to identify all factor analyses reported across the 328 studies. Identification and registration of many of these areas involved a simple transposition of a numerical value (e.g., Cronbach's alpha, or a bivariate correlation from a table). For test areas that involved interpretation of statistical analysis (i.e., Rasch, IRT, measurement invariance), the lead author was assisted by an experienced senior psychometrician (NC) who confirmed or clarified the reported results and interpretation (e.g., consistency of reporting with statistical results, such as correct handling of root mean square of approximation [RMSEA] values). All values and interpretation were compiled into a master spreadsheet for review and consultation by co-authors.
Synthesis of review findings
and subsequently discussed and approved by all authors. The Table 7 legend provides a complete explanation of the components and scoring information. The scoring rubric was generated for each area to summarize the quantity and/or consistency of research evidence, where applicable. For example, a score of 0 referred to the absence of research evidence; a score of 1 indicated that only 1 study was available, and; a score of 2 indicated that 2 or more studies were available. For reliability indices, a study reporting a value of .70 or above was considered generally sufficient for inclusion (Cronbach, 1951; Lance, Butts, & Michels, 2006; Schmitt, 1996) , acknowledging the caveats of this cut-off, e.g., that longer scales tend to have higher alphas (Cicchetti, 1994; Groth-Marnat, 2009 ). For criterion and convergent validity, an association of .3 or above was the cut-off (i.e., moderate; Cohen, 1992) . Scoring was not weighted and thus does not necessarily reflect the overall quality (i.e., validity, reliability, utility) of each tool. Some tools with relatively more highlighted areas may have other specific deficiencies that make them less suitable than other tools. Some tools with fewer highlighted areas may simply reflect that the tool is more recent and therefore has less supporting evidence. Table 1 presents a summary of all 32 tools, including original references and countries of origin, tool components, items, scoring information, and language versions. The tools have been presented in ascending order of publication date, with the non-gaming-specific tools (n=6) positioned separately at the end of the list. This order is used consistently for all tables except for Table 4 , which is re-ordered to match the distribution of total N data in cells (i.e., descending frequencies) for ease of comprehension.
Results
Overview of tools
Inspection of the list of tools and author information shows that some researchers (and/or their respective research teams) have created or contributed to the development of more than one tool. For example, Mark Griffiths (UK) is a named contributor on 5 tools (including 1 short version); Jeroen Lemmens (the Netherlands) is named on 5 tools (including 2 tools with extended versions); and Tony van Rooij (the Netherlands) is named on 2 tools. The most common country of origin was The Netherlands (n=7), followed by South Korea and Germany (n=4 each), and then the United States, United Kingdom, and Hungary (n=3 each). Most tools used continuous response categories, with the most common type being a 5-point scale (n=16). Only 9 tools employ "Yes/No" responses. Most tools (n=22) reported a cut-off score, and most tools (n=29) were reportedly suitable for respondents under the age of 18 years; however, the minimum age varied (n=15 specified 12-13 years of age). Most tools (n=29) were available in non-English languages. Overall, 29 different languages were represented. Table 2 presents a summary of all tools' coverage of the DSM-5 and ICD-11 criteria. This evaluation referred to the 9 criteria for DSM-5 IGD (i.e., preoccupation, withdrawal, tolerance, unsuccessful attempts to stop/limit, loss of interests due to gaming, continued use despite harm, deception, escape, and harm) and the 3 guidelines for ICD-11 GD (6C51) (i.e., impaired control, increasing priority to gaming, and continued use despite harm) and functional impairment (see Section 2.2). This evaluation showed that, overall, there was inconsistent symptom coverage across the 32 tools. With regard to the DSM-5 criteria, the most consistent criterion (n=31 tools; 97%) was "9: Has jeopardised or lost a significant relationship, job, or educational or career opportunity due to gaming." Other common criteria were symptoms 1 (preoccupation), 2 (withdrawal), 3 (unsuccessful attempts), and 8 (escape), with at least 27 tools including each symptom. Only 9 tools included symptom 6 (continued use despite harm). In total, only 8 tools provided coverage of all 9 DSM-5 criteria (i.e., Petry IGD, IGDS9-SF, PIE-9, IGDT-10, CVAT2.0, IGUESS, and DIA).
Coverage of DSM-5 and ICD-11 criteria
With regard to ICD-11 GD guidelines, all 32 tools including at least one item for "1: impaired control over gaming." Most tools (n=28) measured "2: Increasing priority given to gaming to the extent that gaming takes precedence over other life interests and daily activities." As noted for the DSM-5 criteria, only 9 tools included the ICD-11 criterion "3: Continuation or escalation of gaming despite the occurrence of negative consequences." Coverage of specific types of functional impairment was inconsistent. Consistent with King et al.'s (2013) findings, the most common type of impairment referred to negative social consequences (n=30), followed by negative personal (n=20) and occupational (n=18) consequences. Only 5 tools referred to negative financial consequences of gaming (e.g., debt, overspending on game content; see Brooks & Clark, 2019; Zendle & Cairns, 2018 . In total, only 3 tools provided coverage of all 3 ICD-11 guidelines and 4 domains of functional impairment (i.e., Petry IGD, PIE-9, and IGDT-10), and an additional 4 tools covered all 3 ICD-11 guidelines and 3 domains of functional impairment (i.e., IGDS9-SF, SCI-IGD, CVAT2.0, and DIA).
Overall, there were 8 tools that provided total coverage of both the DSM-5 and ICD-11 criteria (i.e., Petry IGD, IGDS9-SF, PIE-9, IGDT-10, SCI-IGD, CVAT2.0, IGUESS, and DIA). Of this list, only 3 tools referred to 4 types of functional impairment (i.e., Petry IGD, PIE-9, and IGDT-10). Table 3 summarizes the empirical research literature (n=320 studies, excluding duplicates) that have employed at least one of the 32 GD tools (NB: Supplementary material 1 presents a list of 328 references, which includes 8 duplicated references (i.e., refs 16-93, 19-95, 39-83, 48-177, 82-84, 88-129, 195-212, 196-213; this duplication occurred during coding phases to disambiguate studies with more extensive information on multiple GD tools and/or study parts (i.e., Study 1, Study 2) to ensure that these data were cross-checked properly prior to entering into master spreadsheets.
The evidence base underlying GD tools
This evaluation provides an overview of a substantial proportion of the empirical GD literature (NB: it was beyond the scope of this review to estimate the overall size of the total empirical GD literature; i.e., including other studies that employ an unnamed or uncited instrument). Table 3 indicates that the GD field has at least 30 longitudinal studies, 71 prevalence studies (i.e., studies that employ nationally representative samples), and 14 intervention studies. Overall, the most frequently used tools, irrespective of study type, were the YIAT (n=62), GAS-7 (n=45), and IGDS9-SF (n=24). The most common tool used in prevalence studies was the GAS-7 (n=18), which was also the most common tool for longitudinal studies (n=12). The YIAT has been used in 39 intervention studies and reports on treatment-seekers at baseline, with the majority (n=37) conducted in China and South Korea.
commentary and debate papers on the topic of consensus on DSM-5 IGD). Similarly, the A-EQ is highly cited (n=798) relative to its use in studies (n=22), which may be attributed to the paper's wider discussion of the importance of distinguishing high (but non-problematic) engagement from addiction (Billieux, Flayelle; Rumpf, & Stein, 2019; Charlton & Danforth, 2007) . Only two GD-specific tools (i.e., the AICA-Sgaming and VAT) have been used in both a national prevalence study and an intervention study. Overall, the YIAT, YDQ, and GAS-7 have been the most widely used and cited GD tools; however, none of these tools provide total coverage of the DSM-5 or ICD-11 criteria. Table 4 presents a summary of the age composition of, and recruitment strategies for, samples in empirical studies of most GD tools (n=24). For this table, tools with only 1 study (n=8) were excluded due to insufficient cases to yield meaningful proportions. Overall, the total N for all identified studies was 462,249 participants, of whom 56% were aged 18 years or older. The GAS-7 has been administered to more participants (n=94,389) than any other tool, including the greatest number of participants recruited using non-convenience sampling (n=55,618). Studies employing the YIAT and YDQ also reported relatively high figures for total N (n=49,509 and n=30,916, respectively) and for participants recruited by non-convenience sampling (n=31,592 and n=29,810, respectively). The AICA-Sgaming was noteworthy for its relatively large evidence base (n=18, including 10 studies with clinical samples), fourth highest total N (36,306), and the highest percentage of non-convenience sampling (85.7%) among the overall most frequently used tools (i.e., ranked 4 th after the GAS-7, YIAT, and CIUS-14). Some tools (i.e., IGDS9-SF, GAS-21, and Petry IGD) have been administered to a relatively large number of participants, but these studies are predominantly based (i.e., >95% of total N) on convenience samples (e.g., online self-selected, non-representative samples). Only the IGUESS tool has total coverage of the DSM-5 and ICD-11 criteria along with an evidence base composed of samples obtained by non-convenience sampling; all other DSM/ICD-compatible tools are based on evidence with 95% convenience sampling.
Samples and recruitment strategies
As a supplementary analysis, all sample figures were examined according to the DSM-5 criteria covered by the tools they had been administered in their respective studies (i.e., based on Table 2 results). The objective of this analysis was to determine the extent to which study participants had been able to respond (e.g., affirmatively, negatively) to specific items referring to GD symptoms. The total N in each study corresponding to each tool was assigned to each of the relevant DSM-5 symptoms covered by each tool. For example, the GAS-7 had been administered to 94,389 participants, and therefore the value 94,389 was assigned to its measurement of symptoms of preoccupation, withdrawal, tolerance, etc. This process yielded an estimated total number of participants with the possibility of responding to any given GD symptom (e.g., assuming the item on the survey was completed).
This evaluation showed that, overall, items referring to preoccupation, withdrawal, unsuccessful attempts, and harm had been administered to >96% of participants across the 320 studies. However, items measuring continued use despite harm (i.e., the DSM-5 and ICD-11 criterion) had been administered to only 11.9% of participants. Similarly, items measuring tolerance (67.6%), loss of interests (58.5%), and deception (48.3%) had been administered to relatively fewer participants across studies. When selecting only those studies with non-convenience samples, these figures were relatively similar across these symptoms (i.e., less than 4% difference), except for the item on J o u r n a l P r e -p r o o f continued use despite harm, which reduced from 11.9% to 1.9%. Only 5053 participants out of the 268,081 participants in non-convenience samples had been administered a tool with an item referring to continued use despite harm, indicating that this symptom was underrepresented in the literature. Table 5 presents the first of two summaries of the psychometric properties of the 32 tools based on their 320 empirical studies. The table summarizes the research evidence on test dimensionality, reliability, and test refinement. Most GD tools (n=27) have been examined using factor analytic techniques (or principal component analysis), but there are inconsistencies across tools in terms of factor analytic (FA) approach. Only 9 tools (i.e., POGU, POGQ, IGD-20, Petry IGD, Lemmens IGD-9 and IGD-27, YDQ, and CIUS-214) have been examined by exploratory followed by confirmatory factor analysis (i.e., EFA and CFA conducted in independent subsamples) within the same study. The majority (n=21) of tools have been subjected to CFA only, with most studies providing the a priori reasoning that GD is a unidimensional construct. The majority of FA studies (n=47) reported that the GD construct is unidimensional (i.e., commonly referring to the GD construct composed of nine DSM-5 criteria, with the caveat that most tools actually assess fewer than 9 criteria; see Table 2 ). There was minimal empirical support for other dimensional structures (e.g., 2-factor solutions; n=3 studies). Some tools demonstrated mixed and/or weak support for their factor structure (e.g., VAT, sIATgaming, .
Psychometric properties of tools
Internal consistency was generally high across the 31 tools (i.e., this was not reported for SCI-IGD). With the exception of the BAM-VG, GAIA, VASC, CIUS-5, CIUS-8 and SSBA tools which had only 1 study reporting on internal consistency, each tool had at least two independent studies reporting Cronbach's alpha values of at least 0.80. Considerably fewer tools (n=7; 9 studies) had examined test-retest reliability; in 8 of these 9 studies, the observed values from a 14-day or 30-day retest were satisfactory. The BAM-VG had a .73 test-retest reliability over a period of 90 days. There were 8 tools (i.e., GAS-7, POGQ, POG-SF, VAT, IGDS9-SF, IGDT-10, CIUS-14, CIUS-8) that had been evaluated by test-refinement analyses (e.g., IRT, Rasch analysis). Generally, these analyses provided support for the model fit and measurement invariance of each respective test. However, the IGDS9-SF reported mixed results for measurement invariance across cultural groups; it bears noting that these data were based largely (>95%) on convenience sampling, which may have affected analyses. Table 6 summarizes the research evidence on test validity, relationship to impairment, and clinical use of each tool. Convergent validity has often been operationalized in the GD literature as the bivariate association between gaming behavior (i.e., hours per week spent gaming) and total score on a GD tool. The research team discussed and agreed that habitual gaming for long periods (e.g., 6 to 8 hours per day, or longer) was typical in the context of GD, and acknowledged that this behavioral pattern may fluctuate and that the condition was often episodic, but did not consider this association to be generally defining. Gaming may occur for some individuals as a regular and relatively frequent activity without reported associated major negative consequences, as described in previous studies (Király, Tóth, Urbán, Demetrovics, & Maraz, 2017; Triberti et al., 2018) . King et al.'s (2013) review J o u r n a l P r e -p r o o f reported the GD-gaming time association for convergent validity; therefore, it is reproduced with caution in this review. Overall, there were varied results on the association between gaming time and total GD tool score, with reported values largely ranging from .2 and .4 (i.e., small to moderate effect; Cohen, 1992) .
Criterion validity was evaluated by examining the association between scores on each GD tool and other similar or closely related tools (e.g., measures of gaming-related craving or maladaptive gaming-related cognitions). Most tools (n=28) have been examined in relation to other GD tools, particularly the YIAT (n=8 tool comparisons). The GAS-21, VAT, and the IGDS9-SF have reported the most consistently high correlations with other GD tools. Aside from the YIAT's consistent convergent validity results across 11 studies, the IGDS9-SF was noteworthy for having 5 studies employing 4 different GD tools (i.e., GAS-7, IGD-20, Lemmens IGD-9, and YIAT) that reported associations exceeding r=.70.
Only 6 tools (n=9 studies) have been examined in conjunction with standardized measures of functional impairment or quality of life. The PIE-9 was the only tool that has been evaluated using the recommended standard disability/impairment assessment (i.e., the World Health Organization-Disability Assessment Schedule [WHO-DAS]). The IGD-20 has been examined in conjunction with the DSM global clinician rating scale (i.e., General Assessment of Functioning [GAF]). Other tools (i.e., the A-EQ, GAS-7, Lemmens IGD-9, and YIAT) have been evaluated using standardized qualityof-life measures.
Eleven tools have been employed in studies involving a clinical interview. Notably, the AICA-Sgaming (n=11) and the YIAT (n=31) have been used most frequently. The AICA-Sgaming and Petry IGD are the two most commonly used gaming-specific tools within studies using clinical interviews. In relation to GD tools measuring treatment outcomes, only the YIAT (n=9 studies) and YDQ (n=2 studies) have been used in more than one published study. Four other GD tools (i.e., the POGU, AICA-Sgaming, VAT, and IGD-20) have been employed in one study only. Table 7 presents a synthesis of the main areas of evaluation of the 32 tools. This table was designed to provide a 'quick guide' for researchers and clinicians, identifying tools with specific supporting evidence or use in particular study types. In this way, the table aims to provide a concise overview of the relative strengths and weaknesses for each tool, with the caveats that this table presents: (1) an unweighted representation of data underlying each of the criteria, meaning that the table does not differentiate between tools that meet certain score thresholds (e.g., 2 studies) and those that greatly exceed this basic threshold (e.g., not all tools that score 2 on 'prevalence data' should be considered equivalent); (2) total scores in the rightmost column should not necessarily be considered an overall indicator of tool quality (i.e., higher scores indicate the presence of research evidence in more areas, not higher tool quality); and, (3) higher scores in some areas may be undermined by weaknesses in other areas (e.g., tools with poorly sampled studies are less likely to be valid).
Quick reference guide to GD tools
Notwithstanding these limitations, the GD tools that fulfilled the most scoring criteria were the GAS-7, IGDS9-SF, IGDT-10, YDQ and Lemmens IGD-9. The GAS-7 is a much older gamingspecific tool and precedes the DSM-5. Although the GAS-7 is still used frequently in research, J o u r n a l P r e -p r o o f particularly in prevalence studies of European young people, this tool has not yet been used in intervention studies. Only the IGDS9-SF and IGDT-10 have DSM-5 and ICD-11 coverage, and only the YDQ has been used in a study involving clinical interviewing or an intervention. The IGDS9-SF and IGDT-10 had similar profiles in this evaluation, including basic length and scoring, and a comparably sized evidence base (i.e., in terms of total N) predominantly based on convenience samples. Overall, there was a mixed picture of the evidence on GD tools, with several tools with relatively higher evidential support in distinct areas (e.g., GAS-7, Lemmens IGD-9, AICA-Sgaming, and IGDT-10), but there was no markedly superior tool with distinct practical and/or psychometric advantages.
Discussion
The present review aimed to systematically evaluate all available instruments for GD. This work was intended to extend a previous major review of GD tools by King et al. (2013) , which closely preceded the inclusion of GD as a condition for further study in the DSM-5. The 2013 review highlighted conceptual inconsistencies across GD tools, as well as gaps in empirical evidence underlying each measures' psychometric properties. Seven years have passed since the preparation of King et al.'s (2013) report, and with the official inclusion of GD as a diagnostic category in the ICD-11 in May 2019, it was considered timely to re-evaluate the state-of-the-art in GD screening and assessment. Overall, this evaluation has found that the GD field has greatly expanded in overall size and its array of GD-specific instrumentation, particularly since 2013, with at least 2 new tools, on average, published in each subsequent year. The field has also continued to employ several internetuse-specific tools (e.g., the YIAT, created in 1998) to screen for gaming-related problems, particularly in East Asia. Overall, no single tool emerged from this evaluation as the clearly optimal choice. However, there were some relatively stronger tools (i.e., the AICA-Sgaming, GAS-7, IGDT-10, IGDS9-SF, and Lemmens IGD-9), identified on the basis of conceptual and/or practical considerations and greater volume of evidential support for their psychometric properties.
The GD field is growing rapidly on a global level. This systematic review has identified 320 empirical studies that have employed a combined total of 32 GD tools, with these studies conducted primarily throughout Europe and East Asia. However, there still appears to be some uncertainty or lack of agreement among GD researchers concerning optimal approaches to screening and J o u r n a l P r e -p r o o f assessment, as indicated by the continuing creation of new tools that vary in scope and content. This review has identified inconsistencies in symptom coverage across 32 tools. Screening tools do not necessarily have to measure all criteria or guidelines for any given condition, including GD, in order to be effective. The objective is usually to capture the essential elements of behaviors in a brief format. This review shows that most GD tools tend to converge on the importance of screening for impaired control over gaming and gaming behavior that jeopardizes a significant relationship, or school or work opportunity. This means, however, that there are some criteria or guidelines for GD that tend to be excluded from tools. Notably, the criterion referring to continued use despite harm (which is included in the DSM-5 and ICD-11 criteria) has appeared in only 9 out of 32 tools. This review found that an estimated 88.1% of participants across 320 studies have not been administered a survey item that captures this particular symptom. The 8 tools that provide total coverage of both the DSM-5 and ICD-11 criteria (i.e., Petry IGD, IGDS9-SF, PIE-9, IGDT-10, SCI-IGD, CVAT2.0, IGUESS, and DIA) have been used in a combined total of only 5 nationally representative prevalence studies, or 7% of the prevalence study literature. These observations raise the issue of adequate representation of GD symptomatology in research, and whether these observed gaps in measurement should be factored into current estimates of incidence and prevalence.
Sixteen GD-specific tools have been created since the recognition of IGD in the DSM-5 in 2013.
However, many research teams have instead opted to use other tools that precede the DSM-5.
Notably, the YIAT and YDQ measures have been used in numerous studies conducted within China and South Korea, particularly those involving clinical interviews to determine eligibility for neuroimaging evaluation and/or interventions. Similarly, research teams in Europe have often employed the GAS-7 for large-scale prevalence and cohort studies. The GD field therefore appears to be shaped by two main types of researchers: (1) those who continue to use older (i.e., pre-DSM-5) tools (i.e., the GAS-7, YIAT, and YDQ) despite the availability of new tools and guidelines for GD; and, (2) those who develop and attempt to validate their own tools which are often conceptually and practically similar, i.e., a tool of between 10 and 20 items that measures a unidimensional addiction construct derived from DSM-5 criteria. Further, regarding (2), the majority of new tools tend to be J o u r n a l P r e -p r o o f psychometrically evaluated exclusively by the researchers who created them. The IGDT-10 and AICA-Sgaming are the only post-DSM-5 tools that have been employed in a study designed to validate psychometric properties by an independent research team. This suggests that there is an isolationist quality to the field's collective efforts to study GD. Many teams appear to be operating in research silos rather than working collaboratively to develop a unified evidence base around a smaller, more manageable subset of measures. Reaching a consensus about the use of specific psychometrically validated screening tools in studies worldwide would not only optimize prevalence estimates, but may also be helpful for studies addressing psychological mechanisms underlying GD and for testing hypotheses on these processes as suggested in theoretical models (e.g., Dong & Potenza, 2014; Wei et al., 2017) . For comparison, the field of gambling disorder, which like GD is a disorder due to addictive behaviors recognized by the ICD-11 (albeit with a more extensive academic history than GD), has coalesced around 8 main tools used between 2000 and 2015 1 (see Calado & Griffiths, 2015) .
GD tools with greater evidential support
This review identified five GD tools that have a relatively greater volume of evidential support for basic psychometric properties compared to other tools. These tools are the GAS-7, IGDS9-SF, IGDT-10, YDQ, and Lemmens IGD-9. However, no one tool appears clearly superior because many of the tools have similar strengths (e.g., the GAS-7 and Lemmens IGD-9 had a comparable evaluation profile), and each tool's limitations were offset by other positive attributes. Some tools are untested in some contexts (e.g., treatment) or have not yet been evaluated psychometrically in some ways (e.g., item response theory). It may be anticipated that future research will address some of these gaps. On the other hand, given that research teams have tended to specialize in particular research areas (e.g., epidemiological, neuroimaging, treatment) and teams have often favored their own tools, some tools appear unlikely to be evaluated in certain types of research. The AICA-Sgaming, for example, has been used in at least 10 studies of treatment-seekers, whereas 17 other tools have not been used in any research involving clinical samples. This situation may eventually lead to divergent streams of evidence for specific tools, such that some tools become the standard for some study types but not others, thereby complicating future tasks of synthesizing evidence across a broad literature.
The GAS-7 was the most frequently positively rated tool (N.B., not to be conflated with psychometric superiority) due to its multiple positive features and large evidence base. Its research base included numerous datasets from prevalence studies throughout Europe, good criterion validity and reliability (internal, test-retest), and satisfactory performance on test refinement analyses (e.g., measurement invariance). However, the GAS-7 has not been used clinically, and therefore its utility as an outcome measure in treatment, or sensitivity to treatment-related changes, has not been investigated. In addition, the GAS-7 has incomplete coverage of DSM-5 and ICD-11 criteria, which may not be essential for screening purposes but remains noteworthy as the field turns its attention to locating measurement approaches consistent with ICD-11 classification. This may include research initiatives that involve developing new screening tools for behaviors that appear to have overlapping features with gaming (e.g., online social media use) by adapting items from existing GD tools 2 .
Of the 5 tools with the broadest empirical support as identified in Table 7 , the IGDS9-SF and IGDT-10 were the only tools that provided total coverage of the DSM-5 and ICD-11 criteria. The IGDS9-SF and IGDT-10 had similar profiles in this evaluation, including number of items and scoring approach, and a comparably sized evidence base (i.e., in terms of total N). Both tools were limited by their study samples; most studies (i.e., 23 out of 24) that employed the IGDS9-SF involved convenience samples, and the IGDT-10 has exclusively been used in convenience samples (i.e., all 7 studies). The IGDT-10 is noteworthy, however, for its numerous language translations and use in relatively more countries, notably China and Japan (N.B., only 2 of the 32 tools have been translated into Japanese). Therefore, the IGDT-10 seems well positioned to bridge the research divide between Western and Eastern countries that is common in the GD literature. With regard to Eastern research, the YIAT and YDQ tools were most commonly used in Chinese studies (i.e., those published in 2 See recent papers on 'scope creep' (Haslam, 2016) and confirmatory bias in connection to the study of behavioral addictions (Billieux et al., 2015) .
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Implications for debates on GD evidence
The present review provides insights that should contribute to ongoing debate on the general quality and attributes of the GD literature. For example, some critics have asserted that the GD evidence base is flawed due to its reliance on convenience samples. A recent 37-author debate paper by van Rooij et al. (2018) , entitled "A weak scientific basis for gaming disorder" argued against the inclusion of GD in ICD-11 on the basis that scientific standards had not been met. Among other issues raised, the authors argued that sampling approaches were inadequate because studies recruited "healthy high-school/college students or non-representative online samples recruited from Internet gaming forums" (p.3). The authors also referred to the example of a Singaporean dataset, published in 2011 (Gentile, 2011) and subsequently used in multiple publications without cross-attribution of the data, to support their contention that the literature suffered from "poor methodological choices that undermine our confidence in the findings" (van Rooij et al., 2018, p.4) . While it is necessary that authors cite specific examples for academic arguments, it is important that such examples do not form the basis for unwarranted generalizations that may then be misconstrued as scientific consensus. The present review's findings did not support this particular criticism regarding sampling. Based on 320 GD studies of which the majority report independent datasets, there was actually a slight majority of participants (N=268,081 or 58% of all participants) recruited using non-convenience sampling methods (e.g., nationally representative studies, stratified sampling by age, region, urbanicity, and treatment-seekers). It is inaccurate to conclude, therefore, that the GD evidence as a whole is fundamentally flawed or "weak" as a consequence of its recruitment strategies and sample sizes.
Indeed, the present review may provide a useful resource for other matters of debate concerning the size and quality of GD evidence.
Future research directions
This review suggests some potential future research avenues to improve GD assessment. As recommended by King et al. (2013) , there is a continued need for high-quality epidemiological and J o u r n a l P r e -p r o o f intervention studies, including within these studies with a focus on sensitivity/specificity estimates.
Studies of gaming behavior should include consistent measures of comorbidity (e.g., to address questions regarding the presence of other mental disorders, such as depression, anxiety, attentiondeficit/hyperactivity or other factors such as past trauma that may affect risk of GD). Similarly, future work should consider not only addictive aspects, but also other relevant perspectives and concepts related to understanding repetitive behaviors, notably impulsivity and compulsivity, in further developing and refining instruments and diagnostic criteria. Non-problematic gaming habits, as well as diagnostically subthreshold entities such as 'hazardous gaming' (QE22) in the ICD-11, deserve closer attention (Potenza, 2018) . The focus of most studies of GD has been on the harmful consequences of gaming, without taking into account the potential benefits of gaming activities for some individuals. GD symptoms and negative consequences of gaming should be weighed against reported benefits of gaming, particularly at lower levels of problematic gaming (e.g., meeting between 1 and 4 DSM-5 criteria). This may determine whether some individuals classified within 'low risk' categories might in fact report that gaming has a net benefit on their quality of life and psychological wellbeing or whether this sub-diagnostic level is associated with more mental health concerns, as is typically the case in gambling disorder (Desai & Potenza, 2018) .
Another avenue for future research is the use of player data in combination with GD tools and related measures. The field has often relied on self-report approaches to validate tools, which has unavoidable limitations (e.g., biased recall, denial/defensiveness, lack of insight). Conventional survey and interview approaches may be supplemented by player data to provide an objective historical account of gaming behavior; i.e., to describe or corroborate patterns of behavior that may otherwise be difficult to recall. Such data may be acquired by using an app-like or similar monitoring device or software. Considerations regarding how to work together with groups from the gaming industry warrant transparent discussion in order to help ensure scientific integrity in academic/industry collaborations (Griffiths & Pontes, 2019; King & Delfabbro, 2019) . Another area for future research concerns the evolving technological nature of modern online video games, particularly the monetization of in-game content (e.g., in-game purchasing, microtransactions, and 'loot boxes'; see King et al., 2019; Zendle & Cairns, 2018) . Problematic gaming that involves interactions with monetized content may be more financially involved and share features in common J o u r n a l P r e -p r o o f Journal Pre-proof with gambling disorder (e.g., spending more than one can afford, borrowing or stealing money) (King & Delfabbro, 2018; King et al., 2019) . GD tools may need to reflect some of these structural elements in gaming activities, such as additional questions to examine different behaviors and consequences related to different types of games and modes of access (e.g., smartphones, virtual reality) (King, Koster, & Billieux, 2019) . The measurement of more in-depth player and gaming information (e.g., game types) is beyond the scope of screening approaches, but is suited to a semi-structured diagnostic interview for GD (i.e., akin to the Structured Clinical Interview for DSM or Mini International Neuropsychiatric Interview), which could be developed and used internationally.
Limitations of the review
The present review has several limitations that should be acknowledged. First, this review was based on English-language studies only, which excluded a significant proportion (i.e., potentially, the majority) of the East Asian literature (i.e., studies in Chinese, Korean, and Japanese, in particular).
This review also did not include data from studies published in German, Dutch, and French. Although researchers working in these countries often publish their work in English journals, the potential omission of relevant data is likely to have affected the evaluation of tools originating from these regions, e.g., the AICA-Sgaming, CSAS, GAS-7, and sIAT-gaming. Similarly, in some countries, there is a substantial grey literature (e.g., government-led health surveys that include standard GD questions), which was not included in this review. This review also did not include studies that employed "adapted" DSM-5 criteria, which would not have affected the main evaluation of tools, but should be taken into account when considering this review's observations of the broader GD literature (e.g., total number of prevalence studies). The review framework aimed to be more comprehensive than any previous review but there were still some gaps. This review did not consider, for example, the sensitivity/specificity of tools, because: (1) this information was very rarely reported; and, (2) the external standard was not always clear in relevant studies. Other areas that were not evaluated were predictive and divergent validity, due to inconsistencies in reporting that made it difficult to extract these data. This review takes into consideration the current conceptualizations of GD and IGD, which may be revised as more evidence accumulates. Finally, the review framework itself was limited by the J o u r n a l P r e -p r o o f Journal Pre-proof fact that many of the criteria were inter-related and often affected by other considerations (e.g., sampling method, sample size).
Conclusions
The inclusion of GD in the ICD-11 was a significant milestone for the field. The GD diagnosis is likely to stimulate new research investigations on a global level, in important areas of epidemiology, neurobiology, treatment, prevention and public health. The present review aimed to inform the next era of research by providing a comprehensive evaluation of all available English-language GD tools, including a critical appraisal of their associated empirical evidence. The framework employed in this review may be useful for scale evaluation in other areas. Overall, this evidence was found to be mixed, with no clearly optimal tool among 32 tools used across Western and Eastern countries. While the research base has grown rapidly and largely improved its methodologies, the field is hindered by the overproduction of conceptually similar tools which have divided research efforts and created uncertainty among researchers. Despite the abundance of new instrumentation, some tools have relatively greater evidential support for their psychometric properties, including the GAS-7, IGDS9-SF, IGDT-10, and Lemmens IGD-9. Given that most new tools were developed following the inclusion of the provisional DSM-5 criteria, it seems likely that researchers will again "rush to market" to develop new tools that purportedly measure the new ICD-11 GD classification. For the field to prosper and attain greater legitimacy in the field of addiction studies, a more unified approach to measurement is important. Isolated research that creates a multiplicity of tools generates an incohesive and less convincing evidence base. The development of a gold standard tool, following past examples of screening for use of addictive substances (e.g., Saunders et al., 1993; ASSIST; WHO ASSIST Working Group, 2002) , would be invaluable for steering this nascent field toward achieving valid identification of gaming-related harms, and developing more effective intervention strategies for those in need. (Table 7) . DLK wrote the first draft of the manuscript, and all authors contributed to and approved the final manuscript.
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